Risperidone

Generic Name: Risperidone

Brand Names: Perseris, Risperdal, Rykindo, Uzedy, Okedi

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₇FN_₄O_₂

CAS Number: 106266-06-2

Unique Ingredient Identifier: L6UH7ZF8HC

Background: Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. Paliperidone, another commonly used SGA, is the primary active metabolite of risperidone (i.e. 9-hydroxyrisperidone).
...

Indication: Risperidone is indicated for the treatment of schizophrenia and irritability associated with autistic disorder. It is also indicated as monotherapy, or adjunctly with lithium or valproic acid, for the treatment of acute mania or mixed episodes associated with bipolar I disorder.
...

Associated Conditions: Acute Mania, Irritability, Mixed manic depressive episode, Psychosis, Schizophrenia, Acute Manic episode, Agitated psychotic state

Associated Therapies: -

Clinical Trials

Integrating Psychotropic Medication Into the Care of People With Mental Disorders in a Prayer Camp in Ghana

Phase 4

Completed

Conditions: Anxiety Disorder
Schizophrenia
Mood Disorders,

Interventions: Drug: olanzapine
Drug: risperidone
Drug: amitryptaline
Drug: fluoxetine

First Posted Date: 2015-11-01

Last Posted Date: 2015-11-01

Lead Sponsor: University of Ghana Medical School

Target Recruit Count: 139

Registration Number: NCT02593734

Locations: 🇬🇭
Mount Horeb Prayer Centre, Mamfe, Ghana

Antipsychotics and Risk of Hyperglycemic Emergencies

Completed

Conditions: Schizoaffective Disorder
Psychotic Disorders
Diabetes Mellitus, Type 2
Schizophrenia
Bipolar Disorder

Interventions: Drug: atypical antipsychotics (other)
Drug: typical antipsychotics
Drug: Olanzapine
Drug: Risperidone

First Posted Date: 2015-10-21

Last Posted Date: 2015-10-21

Lead Sponsor: Canadian Network for Observational Drug Effect Studies, CNODES

Target Recruit Count: 725489

Registration Number: NCT02582736

Locations: 🇨🇦
Women's College Hospital, Women's College Research Institute, Toronto, Ontario, Canada

Clozapine Versus Other Atypical Antipsychotics for Bipolar Disorder

Phase 4

Conditions: Bipolar Disorder

Interventions: Drug: Clozapine
Drug: Risperidone
Drug: Olanzapine
Drug: Quetiapine

First Posted Date: 2015-09-29

Last Posted Date: 2018-10-02

Lead Sponsor: Hospital de Clinicas de Porto Alegre

Target Recruit Count: 54

Registration Number: NCT02562287

Locations: 🇧🇷
Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil

Schizotypal Personality Disorder Risperidone

Phase 1

Completed

Conditions: Schizotypal Personality Disorder

Interventions: Drug: Risperidone
Drug: Placebo

First Posted Date: 2015-08-28

Last Posted Date: 2017-08-11

Lead Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Target Recruit Count: 21

Registration Number: NCT02535156

Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 1-year Follow-up

Phase 4

Conditions: Schizophrenia
Psychotic Disorders

Interventions: Drug: Aripiprazole
Drug: Risperidone

First Posted Date: 2015-08-25

Last Posted Date: 2020-02-12

Lead Sponsor: Fundación Marques de Valdecilla

Target Recruit Count: 200

Registration Number: NCT02532491

Locations: 🇪🇸
University Hospital Marques de Valdecilla, Santander, Cantabria, Spain

A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment

Phase 3

Completed

Conditions: Schizophrenia

Interventions: Drug: ITI-007
Drug: Risperidone
Drug: Placebo

First Posted Date: 2015-06-11

Last Posted Date: 2017-11-14

Lead Sponsor: Intra-Cellular Therapies, Inc.

Target Recruit Count: 696

Registration Number: NCT02469155

Locations: 🇺🇸
Clinical Site, Long Beach, California, United States

A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry

Phase 2

Terminated

Conditions: Schizophrenia
Schizoaffective Disorder

Interventions: Drug: Aripiprazole
Drug: Olanzapine
Drug: Paliperidone
Drug: Quetiapine
Drug: Risperidone

First Posted Date: 2015-06-04

Last Posted Date: 2017-03-29

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 9

Registration Number: NCT02462473

Controlled Trial of Valproate Versus Risperidone in Young Children With Bipolar Disorder

Phase 3

Completed

Conditions: Bipolar Disorder

Interventions: Drug: Placebo
Drug: Risperidone
Drug: Valproic Acid

First Posted Date: 2015-05-28

Last Posted Date: 2018-12-12

Lead Sponsor: Nationwide Children's Hospital

Target Recruit Count: 46

Registration Number: NCT02456454

Risperidone-controlled,Multicentre Clinical Trial of Iloperidone in Patients With Schizophrenia

Phase 3

Conditions: Schizophrenia

Interventions: Drug: Iloperidone
Drug: Risperidone

First Posted Date: 2015-05-27

Last Posted Date: 2015-05-27

Lead Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Target Recruit Count: 288

Registration Number: NCT02453893

Locations: 🇨🇳
Shanghai Mental Health Center, Shanghai, Shanghai, China

Neuroendocrine and Metabolite Substrates in Schizophrenia

Conditions: Schizophrenia

Interventions: Drug: Risperidone

First Posted Date: 2015-04-22

Last Posted Date: 2016-11-10

Lead Sponsor: Chang Gung Memorial Hospital

Target Recruit Count: 200

Registration Number: NCT02423096

Locations: 🇨🇳
Liang-Jen Wang, Kaohsiung, Taiwan

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy